Kotyla, Przemysław J.Islam, Md AsifulEngelmann, Małgorzata2024-09-232024-09-232020-10-07Kotyla PJ, Islam MA, Engelmann M. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences. 2020; 21(19):7390. https://doi.org/10.3390/ijms211973901422-006733036382 (pubmed)10.3390/ijms21197390http://hdl.handle.net/2436/625677© 2020 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/ijms21197390Janus kinase (JAK) inhibitors, a novel class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), have shown their safety and efficacy in rheumatoid arthritis (RA) and are being intensively tested in other autoimmune and inflammatory disorders. Targeting several cytokines with a single small compound leads to blocking the physiological response of hundreds of genes, thereby providing the background to stabilize the immune response. Unfortunately, blocking many cytokines with a single drug may also bring some negative consequences. In this review, we focused on the activity of JAK inhibitors in the cardiovascular system of patients with RA. Special emphasis was put on the modification of heart performance, progression of atherosclerosis, lipid profile disturbance, and risk of thromboembolic complications. We also discussed potential pathophysiological mechanisms that may be responsible for such JAK inhibitor-associated side effects.application/pdfenLicence for published version: Creative Commons Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/rheumatoid arthritisJanus Kinase inhibitorscardiovascular systemheart failurethromboemboliclipid profile disturbancescytokinesCardiovascular SystemAnimalsHumansArthritis, RheumatoidCardiovascular DiseasesDisease SusceptibilityAntirheumatic AgentsInflammation MediatorsCytokinesImmunityAutoimmunityLipid MetabolismSTAT Transcription FactorsJanus KinasesJanus Kinase InhibitorsJournal article1422-0067International Journal of Molecular Sciences2024-09-18